Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.

Read the article about Annexin Pharmaceuticals here:

https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/annexin-pharmaceuticals-ab/r/biostock--annexin-s-phase-ii-study-fully-recruited-with-positive-signals,c3970189

(c) 2024 Cision. All rights reserved., source Press Releases - English